drugset / Trial / NCT00304018
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
Phase 1
Completed
5 enrolled
University of California, San Francisco
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Giving chemotherapy, such as fludarabine, busulfan, and etoposide, before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving antithymocyte globulin before transplant and tacrolimus and prednisone after transplant may stop this from happening. PURPOSE: This phase I trial is studying how well donor umbilical cord blood transplant works in treating patients with advanced hematologic cancer.
Timeline
- Start
- 2002-10
- Primary completion
- 2009-03
- Completion
- 2009-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | — | Intravenous |
| Background | Busulfan | Small molecule | — | Intravenous |
| Background | Etoposide | Small molecule | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |
| Background | Prednisone | Other / unclassified | — | Oral |
| Background | Tacrolimus | Small molecule | — | Intravenous |
| Background | sargramostim | Protein / enzyme biologic | — | Intravenous |